EIKN Latest Press Releases

-- November 12, 2026 --

Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates Globe Newswire 6:30 AM

-- November 2, 2026 --

Eikon Therapeutics to Participate in Multiple Investor Conferences in November Globe Newswire 9:15 AM

-- October 26, 2026 --

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress Globe Newswire 6:00 AM

-- October 23, 2026 --

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress Globe Newswire 9:15 AM

-- October 18, 2026 --

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress Globe Newswire 6:05 PM

-- October 15, 2026 --

Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer Globe Newswire 8:00 AM

-- September 3, 2026 --

Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer Globe Newswire 7:30 AM

-- August 26, 2026 --

Eikon Therapeutics to Participate in Investor Conferences in September 2026 Globe Newswire 7:30 AM

-- August 18, 2026 --

Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald Globe Newswire 4:15 PM

-- August 13, 2026 --

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates Globe Newswire 4:02 PM

-- August 11, 2026 --

Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma Globe Newswire 7:30 AM

-- August 10, 2026 --

Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board Globe Newswire 7:30 AM

-- July 27, 2026 --

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer Globe Newswire 7:30 AM

-- July 20, 2026 --

Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress Globe Newswire 8:00 AM

-- June 25, 2026 --

Eikon Therapeutics to Join the Russell 3000 Index Globe Newswire 4:15 PM

Market Data Delayed 15 Minutes